Current awareness of piperazines: Pharmacology and toxicology

Drug Testing and Analysis

Volumn 3, Issue 7-8, 2011, Pages 430-438

  Elliott, Simon ^a  

^a Inverness Medical Innovations   (United States)

Author keywords

BZP; Piperazines; TFMPP

Indexed keywords

'CURRENT; 1-BENZYLPIPERAZINE; BIOLOGICAL FLUIDS; CYTOCHROMES P450; GLUCURONIDATION; PIPERAZINE; PIPERAZINE DERIVATIVES; SULPHATION; TFMPP; TOXIC EFFECT;

BLOOD;

(3 CHLOROPHENYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1 (3,4 METHYLENEDIOXYBENZYL)PIPERAZINE; 1 (4 FLUOROPHENYL)PIPERAZINE; 1 (4 METHOXYPHENYL)PIPERAZINE; 1 BENZYLPIPERAZINE DERIVATIVE; CYTOCHROME P450; PLACEBO; UNCLASSIFIED DRUG;

AGITATION; ANXIETY DISORDER; APPETITE DISORDER; BEHAVIORAL RESEARCH; BLOOD ANALYSIS; BLOOD PRESSURE; CLINICAL TRIAL; COLLAPSE; CONFUSION; DIZZINESS; DRUG ABUSE; DRUG FATALITY; DRUG METABOLISM; DYSPHORIA; EUPHORIA; GLUCURONIDATION; HALLUCINATION; HEADACHE; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPERTENSION; IRRITABILITY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH PAIN; SULFATION; SWEATING; TACHYCARDIA;

EID: 79960637052     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.307     Document Type: Review

References (70)

1. D de Boer, I.J Bosman, E Hidvegi, C Manzoni, A.A Benko, L.J.A.L dos Reys, R.A.A Maes. Piperazine-like compounds: a new group of designer drugs of abuse on the European market. Forensic Sci. Int. 2001, 121, 47.
2. L.A King, D Nutt. Seizures in a night club (letter). The Lancet 2007, 370, 220.
3. S Elliott, C Smith. Investigation of the first deaths in the UK involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J. Anal. Toxicol. 2008, 32, 172.
4. M.H Fong, S Garattini, S Caccia. 1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole. J. Pharm. Pharmacol. 1982, 34, 674.
5. K Tekes, L Tothfalusi, B Malomvolgyi, F Herman, K Magyar. Studies on the biochemical mode of action of EGYT-475, a new antidepressant. Pol. J. Pharmacol. Pharm. 1987, 39, 203.
6. M Wikstrom, P Holmgren, J Ahlner. A2 (N-Benzylpiperazine) a new drug of abuse in Sweden. J. Anal. Toxicol. 2004, 28, 67.
7. P Gee, S Richardson, W Woltersdorf, G Moore. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N. Z. Med. J. 2005, 118, U1784.
8. C Wilkins, M Girling, P Sweetsur, T Huckle, J Haukau. Legal Party Pill use in New Zealand: Prevalence of Use, Availability, Health Harms and 'Gateway Effects' of Benzylpiperazine (BZP) and Trifluorophenylmethylpiperazine (TFMPP), National Household Survey, Centre for Social and Health Outcomes Research and Evaluation (SHORE), Massey University: New Zealand, 2006.
9. S Kenyon, J Button, J Ramsey, D.W Holt. 'Legals highs'-analysis of tablets and capsules containing piperazines, poster presentation, LTG December Meeting, London, UK, 2006, Available at: Accessed March 2011.
10. EMCDDA Annual Report Available at: [Accessed December 2010].
11. J Sheridan, R Butler, C Wilkins, B Russell. Legal piperazine-containing party pills-a new trend in substance misuse. Drug Alcohol Rev. 2007, 26, 335.
12. C Bye, A.D Munro-Faure, A.W Peck, P.A Young. A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance test. Eur. J. Clin. Pharmacol. 1973, 6, 163.
13. H Campbell, W Cline, M Evans, J Lloyd, A.W Peck. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur. J. Clin. Pharmacol. 1973, 6, 170.
14. Z Szucks, T Szentendrei, M.I Fekete. The effect of EGYT-475 (Trelibet) and its metabolites on the potassium-stimulated 3H-noradrenaline release from cortical slices of rat brain. Pol. J. Pharmacol. Pharm. 1987, 39, 185.
15. K Magyar. Pharmacokinetic aspects of the mode of action of EGYT-475, a new antidepressant agent. Pol. J. Pharmacol. Pharm. 1987, 39, 107.
16. B Malomvolgyi, L Tothfalusi, K Tekes, K Magyar. Comparison of serotonin agonistic and anatagonistic activities of a new antidepressant agent Trelibet (EGYT-475) and its metabolite EGYT-2760 on isolated rat fundus. Acta Physiol. Hung. 1991, 78, 201.
17. C Oberlander, C Euvrard, C Dumont, J.R Boissier. Circling behaviour induced by dopamine releasers and/or uptake inhibitors during degeneration of the nigrostriatal pathway. Eur. J. Pharmacol. 1979, 60, 163.
18. M.H Baumann, R.D Clark, A.G Budzynski, J.S Partilla, B.E Blough, R.B Rothman. Effects of 'Legal X' piperazine analogs on dopamine and serotonin release in rat brain, Ann. N.Y. Acad. Sci. 2004, 1025 189.
19. M.H Baumann, R.D Clark, A.G Budzynski, J.S Partilla, B.E Blough, R.B Rothman. N-Substituted piperazines abused by humans mimic the molecular mechanism of 3, 4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'), Neuropsychopharmacology. 2005, 30, 550.
20. K Hashimoto, H Maeda, T Goromaru. Effects of benzylpiperazine derivatives on the neurotoxicity of 3, 4-methylenedioxymethamphetamine in rat brain. Brain Res. 1992, 590, 341.
21. D.L Murphy, K.P Lesch, C.S Aulakh, T.A Pigott. Serotonin-selective arylpiperazines with neuroendocrine, behavioural, temperature, and cardiovascular effects in humans. Pharmacol. Rev. 1991, 43, 527.
22. N Ghaziuddin, K Welch, J Greden. Central serotonergic effects of m-chlorophenylpiperazine (mCPP) among normal control adolescents. Neuropsychopharmacology. 2003, 28, 133.
23. A Hamik, S.J Peroutka. 1-(m-chlorophenylpiperazine) (mCPP) interactions with neurotransmitter receptors in the human brain. Biol. Psychiatry. 1989, 25, 569.
24. L.K Aitchison, R.N Hughes. Treatment of adolescent rats with 1-benzylpiperazine: a preliminary study of subsequent behavioral effects. Neurotoxicology and Teratology, 2006, 28, 453.
25. E Meririnne, M Kajos, A Kankaanpaa, T Seppala. Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats. Basic Clin. Pharmacol. Toxicol. 2006, 98, 346.
26. K Brennan, A Johnstone, P Fitzmaurice, R Lea, S Schenk. Chronic benzylpiperazine (BZP) exposure produces behavioural sensitization and cross-sensitization to methamphetamine (MA). Drug Alcohol Depend. 2007, 88, 204.
27. H.L Yarosh, E.B Katz, A Coop, W.E Fantegrossi. MDMA-like behavioral effects of N-substituted piperazines in the mouse. Pharmacol. Biochem. Behav. 2007, 88, 18.
28. W.E Fantegrossi, G Winger, J.H Woods, W.L Woolverton, A Coop. Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend. 2005, 77, 161.
29. K.A Brennan, B Lake, L.S Hely, K Jones, D Gittings, J Colussi-Mas, P.S Fitzmaurice, R.A Lea, S Schenk. N-benzylpiperazine has characteristics of a drug of abuse. Behav. Pharmacol. 2007, 18, 785.
30. J.C Lin, R.K Jan, H Lee, M.A Jensen, R.R Kydd, B.R Russell. Determining the subjective and physiological effects of BZP combined with TFMPP in human males. Psychopharmacology (Berl). 2011, 214, 761.
31. J.C Lin, N Bangs, H Lee, R.R Kydd, B.R Russell. Determining the subjective and physiological effects of BZP on human females. Psychopharmacology (Berl). 2009, 207, 439.
32. I Thompson, G Williams, B Caldwell, S Aldington, S Dickson, N Lucas, J McDowall, M Weatherall, G Robinson, R Beasley. Randomised double-blind, placebo-controlled trial of the effects of the 'party pills' BZP/TFMPP alone and in combination with alcohol. J. Psychopharmacol. 2010, 24, 1299.
33. U Antia, M.D Tingle, B.R Russell. 'Party pill' drugs-BZP and TFMPP. N.Z. Med. J. 2009, 122, 55.
34. M Alansari, D Hamilton. Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. N.Z. Med. J. 2006, 119, U1959.
35. R.S Kahn, S Wetzler, m-Chlorophenylpiperazine as a probe of serotonin function. Biol. Psychiatry 1991, 30, 1139.
36. M.E Tancer, C.E Johanson. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend. 2001, 65, 97.
37. U Antia, M.D Tingle, B.R Russell. Metabolic interactions with piperazine-based 'party pill' drugs. J. Pharm. Pharmacol. 2009, 61, 877.
38. R.F Staack, G Fritschi, H.H Maurer. Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J. Chrom. B 2002, 773, 35.
39. H.H Maurer, T, Kraemer, D Springer, R.F Staack. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther. Drug Monit. 2004, 26, 127.
40. H Tsutsumi, M Katagi, A Miki, N Shima, T Kamata, M Nishikawa, K Nakajima, H Tsuchihashi. Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine. J. Chrom. B 2005, 819, 315.
41. R.F Staack, G Fritschi, H.H Maurer. New designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolites and on its toxicological detection in rat urine. J. Mass Spectrom. 2003, 38, 971.
42. U Antia, H.S Lee, R.R Kydd, M.D Tingle, B.R Russell. Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Sci. Int. 2009, 186, 63.
43. U Antia, M.D Tingle, B.R Russell. Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. J. Forensic Sci. 2010, 55, 1311.
44. R.F Staack, H.H Maurer. New designer drug 1-(3, 4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom. 2004, 39, 255.
45. R.F Staack, H.H Maurer. Studies on the metabolism and the toxicological analysis of the nootropic drug fipexide in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004, 804, 337.
46. R.F Staack, D.S Theobald, L.D Paul, D Springer, T Kraemer, H.H Maurer. In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step. Xenobiotica 2004, 34, 179.
47. R.F Staack, H.H Maurer. Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 798, 333.
48. R.F Staack, H.H Maurer. Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine includinf analytical differentiation from its precursor drugs trazodone and nefazodone. J. Anal. Toxicol. 2003, 27, 560.
49. S Rotzinger, J Fang, R.T Coutts, G.B Baker. Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol. Psychiatry 1998, 44, 1185.
50. Z Yan, G.W Caldwell, W.N Wu, L.A McKown, B Rafferty, W Jones, J.A Masucci. In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone. Xenobiotica 2002, 32, 949.
51. A.S Kalgutkar, A.D Vaz, M.E Lame, K.R Henne, J Soglia, S.X Zhao, Y.A Abramov, F Lombardo, C Collin, Z.S Hendsch, C.E Hop. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab. Dispos. 2005, 33, 243.
52. E Hollander, C DeCaria, R Gully, A Nitescu, R.F Suckow, J.M Gorman, D.F Klein, M.R Liebowitz. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res. 1991, 36, 1.
53. A Feuchtl, M Bagli, R Stephan, C Frahnert, H Kölsch, K.U Kühn, M.L Rao. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. Pharmacopsychiatry 2004, 37, 180.
54. H.J Gijsman, J.M Van Gerven, M.C Tieleman, R.C Schoemaker, M.S Pieters, M.D Ferrari, A.F Cohen, G.M Van Kempen. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. J. Clin. Psychopharmacol. 1998, 18, 289.
55. S.C Bishop, B.R McCord, S.R Gratz, J.R Loeliger, M.R Witkowski. Simultaneous separation of different types of amphetamine and piperazine designer drugs by capillary electrophoresis with a chiral detector. J. Forensic Sci. 2005, 50, 326.
56. J Aunan, R Ely. The forensic examination of benzylpiperazine and phenylpiperazine homologs, presented at the 9th Annual Clandestine Laboratory Investigating Chemists Association (CLIC) Technical Training Seminar, 8-11 September, Toronto, Ontario, Canada, 1999.
57. H.H Maurer. Mass spectra of select benzyl- and phenyl-piperazine designer drugs. Microgram J. 2004, 2, 22.
58. S Kenyon. Analytical profiles of the piperazines. LTG monograph. 2007, Available at: Accessed March 2011.
59. A Wohlfarth, W Weinmann, S Dresen. LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum. Anal. Bioanal. Chem. 2010, 396, 2403.
60. F.T Peters, S Schaefer, R.F Staack, T Kraemer, H.H Maurer. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry, J. Mass Spec. 2003, 38, 659.
61. H Inoue, Y.T Iwata, T Kanamori, H Miyaguchi, K Tsujikawa ., K Kuwayama, H Tsutsumi, M Katagi, H Tsuchihashi, T Kiski. Analysis of benzylpiperazine-like compounds. Japanese J. Forensic Sci. Technol. 2004, 9, 165.
62. H.K Nordgren, P Holmgren, P Liljeberg, N Eriksson, O Beck. Application of direct urine LC-MS-MS-analysis for screening of novel substances in drug abusers. J. Anal. Toxicol. 2005, 29, 234.
63. J Button, D Wood, P.I Dargan, H Ovaska, A.L Jones, J Ramsey, D.W Holt. A gas hromatographic mass-spectrometric method for the quantitative analysis of the recreational drug N-benzylpiperazine in serum, poster presentation. LTG December meeting, London, UK, 2006, Available at: Accessed March 2011.
64. J Kovaleva, E Devuyst, P De Paepe, A Verstraete. Acute chlorophenylpiperazine overdose: a case report and review of the literature. Ther. Drug Monit. 2008, 30, 394.
65. F Durand, D Samuel, J Bernuau, F Saliba, E.A Pariente, S Marion, J.P Benhamou, H Bismuth. Fipexide-induced fulminant hepatitis. Report of three cases with emergency liver transplantation. J. Hepatol. 1992, 15, 144.
66. P Gee, T Jerram, D Bowie. Multiorgan failure from 1-benzylpiperazine ingestion-legal high or lethal high? Clin. Toxicol. (Phila). 2010, 48, 230.
67. P Gee, M Gilbert, S Richardson, G Moore, S Paterson, P Graham. Toxicity from the recreational use of 1-benzylpiperazine. Clin. Toxicol. (Phila). 2008, 46, 802.
68. D Wood, P.I Dargan, J Button, D.W Holt, H Ovaska, J Ramsey, A.L Jones. Collapse, reported seizure-and an unexpected pill. The Lancet 2007, 369, 1490.
69. D.M Wood, J Button, S Lidder, J Ramsey, D.W Holt, P.I Dargan. Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP). J. Med. Toxicol. 2008, 4, 254.
70. C Balmelli, H Kupferschmidt, K Rentsch, M Schneemann. Fatal brain edema after ingestion of ecstasy and benzylpiperazine. Dtsch. Med. Wochenschr. 2001, 126, 809.